We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Anixa Biosciences (ANIX) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is ANIXA BIOSCIENCES INC (ANIX - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
ANIXA BIOSCIENCES INC is one of 951 companies in the Medical group. The Medical group currently sits at #5 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. ANIXA BIOSCIENCES INC is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ANIX's full-year earnings has moved 2.6% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the latest available data, ANIX has gained about 71.1% so far this year. Meanwhile, stocks in the Medical group have gained about 0.8% on average. This means that ANIXA BIOSCIENCES INC is performing better than its sector in terms of year-to-date returns.
Another Medical stock, which has outperformed the sector so far this year, is Boston Scientific (BSX - Free Report) . The stock has returned 10.7% year-to-date.
Over the past three months, Boston Scientific's consensus EPS estimate for the current year has increased 2%. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, ANIXA BIOSCIENCES INC belongs to the Medical - Biomedical and Genetics industry, a group that includes 469 individual companies and currently sits at #97 in the Zacks Industry Rank. On average, this group has gained an average of 10.2% so far this year, meaning that ANIX is performing better in terms of year-to-date returns.
On the other hand, Boston Scientific belongs to the Medical - Products industry. This 84-stock industry is currently ranked #150. The industry has moved +1.4% year to date.
Going forward, investors interested in Medical stocks should continue to pay close attention to ANIXA BIOSCIENCES INC and Boston Scientific as they could maintain their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Anixa Biosciences (ANIX) Stock Outpacing Its Medical Peers This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is ANIXA BIOSCIENCES INC (ANIX - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
ANIXA BIOSCIENCES INC is one of 951 companies in the Medical group. The Medical group currently sits at #5 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. ANIXA BIOSCIENCES INC is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ANIX's full-year earnings has moved 2.6% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the latest available data, ANIX has gained about 71.1% so far this year. Meanwhile, stocks in the Medical group have gained about 0.8% on average. This means that ANIXA BIOSCIENCES INC is performing better than its sector in terms of year-to-date returns.
Another Medical stock, which has outperformed the sector so far this year, is Boston Scientific (BSX - Free Report) . The stock has returned 10.7% year-to-date.
Over the past three months, Boston Scientific's consensus EPS estimate for the current year has increased 2%. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, ANIXA BIOSCIENCES INC belongs to the Medical - Biomedical and Genetics industry, a group that includes 469 individual companies and currently sits at #97 in the Zacks Industry Rank. On average, this group has gained an average of 10.2% so far this year, meaning that ANIX is performing better in terms of year-to-date returns.
On the other hand, Boston Scientific belongs to the Medical - Products industry. This 84-stock industry is currently ranked #150. The industry has moved +1.4% year to date.
Going forward, investors interested in Medical stocks should continue to pay close attention to ANIXA BIOSCIENCES INC and Boston Scientific as they could maintain their solid performance.